US2789938A - Method of producing a diuretic effect with p-carboxybenzenesulfonamide - Google Patents
Method of producing a diuretic effect with p-carboxybenzenesulfonamide Download PDFInfo
- Publication number
- US2789938A US2789938A US322356A US32235652A US2789938A US 2789938 A US2789938 A US 2789938A US 322356 A US322356 A US 322356A US 32235652 A US32235652 A US 32235652A US 2789938 A US2789938 A US 2789938A
- Authority
- US
- United States
- Prior art keywords
- carboxybenzenesulfonamide
- sodium
- ions
- composition
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- UCAGLBKTLXCODC-UHFFFAOYSA-N carzenide Chemical compound NS(=O)(=O)C1=CC=C(C(O)=O)C=C1 UCAGLBKTLXCODC-UHFFFAOYSA-N 0.000 title claims description 51
- 238000000034 method Methods 0.000 title claims description 9
- 230000001882 diuretic effect Effects 0.000 title description 3
- 208000004880 Polyuria Diseases 0.000 title description 2
- 239000011734 sodium Substances 0.000 claims description 19
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 18
- 150000002500 ions Chemical class 0.000 claims description 12
- 230000008030 elimination Effects 0.000 claims description 10
- 238000003379 elimination reaction Methods 0.000 claims description 10
- 229910001414 potassium ion Inorganic materials 0.000 claims description 10
- 229910001415 sodium ion Inorganic materials 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 7
- 230000014759 maintenance of location Effects 0.000 claims description 7
- 239000003792 electrolyte Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 239000013543 active substance Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 3
- 239000008126 dulcin Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000015598 salt intake Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- CSDXOGPIGCMWCZ-UHFFFAOYSA-N 2-methoxy-4-sulfamoylbenzoic acid Chemical compound COC1=CC(S(N)(=O)=O)=CC=C1C(O)=O CSDXOGPIGCMWCZ-UHFFFAOYSA-N 0.000 description 1
- KDNIOKSLVIGAAN-UHFFFAOYSA-N 2-sulfamoylbenzoic acid Chemical compound NS(=O)(=O)C1=CC=CC=C1C(O)=O KDNIOKSLVIGAAN-UHFFFAOYSA-N 0.000 description 1
- LQOXNXRLHXIPRE-UHFFFAOYSA-N 3-(hydrazinecarbonyl)benzenesulfonamide Chemical compound NNC(=O)C1=CC=CC(S(N)(=O)=O)=C1 LQOXNXRLHXIPRE-UHFFFAOYSA-N 0.000 description 1
- NAETXYOXMDYNLE-UHFFFAOYSA-N 3-sulfamoylbenzoic acid Chemical compound NS(=O)(=O)C1=CC=CC(C(O)=O)=C1 NAETXYOXMDYNLE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 150000003112 potassium compounds Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- -1 sodium cations Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
Definitions
- This invention relates to diuretic compositions, and more particularly to a composition containing an agent which serves to increase the elimination of cations, principally sodium and potassium.
- the invention also involves the process of increasing the elimination of cations, and more particularly the sodium cation, from the body of man or other animals. This process involves the administration of the active agent and the regulation of the quantity consumed so as to bring about this desired result.
- compositions which, when consumed, makes it possible for a person to apply the desired amounts of salt to his food.
- the composition of the invention serves to provide for excretion of a major amount of this salt intake with the result that the patient is allowed a diet to which he will adhere and at the same time the daily salt balance approximates that resulting from moderate to severe salt restriction without the aid of this invention.
- composition of the invention there are a number of clinical indications for the use of the composition of the invention.
- various edematous states it is desirable to eliminate cations, and principally the sodium cations, from the body, in order to bring about a reduction of the edematous condition.
- the composition of the invention By giving such a patient the composition of the invention, this condition will be markedly improved.
- composition of the invention may be particularly useful in the patient prone to congestive heart failure.
- the active agent of the composition of the invention is para-carboxybenzenesulfonamide (or 'para-sulfamylbenzoic acid), having the structural formula:
- This active agent may be combined with either a solid or a liquid carrier or diluent.
- the resulting compound may be put up in the form of tablets, powder, or capsules, or in any form which can be used for oral consumption.
- the liquid preparation may be bottled or even put up in encapsulated form for ease of oral administration.
- the liquid form may as well be for parenteral administration and in this event precautions should of course be taken to produce a sterile composition.
- the active ingredient may be either in complete solution or may be in suspension.
- the unit dosage of the composition should contain therapeutic amounts of the active agent.
- a unit dosage of the ingredient will contain from 10 mg. to 16 gm., a more preferred range being from 100 mg. to 4.0 gm.
- the total daily oral intake for an adult should be from 0.5 to 16 grams, and most generally from 2 to 8 grams. About one-fourth these amounts would be taken parenterally.
- a person required to take this composition will ordinarily prefer at one time to take one or a few tablets or capsules, or one or a few tablespoons of a liquid preparation, or a few cc. of an injectable preparation, the frequency of administration is apparent.
- compositions are provided which are free of any material amounts of sodium or potassium.
- a primary purpose of the invention is to increase the elimination of these cations, it follows that it would be desirable not to introduce any sodium or potassium into the person with the active agent of the invention.
- ordinary pharmaceutical compositions contain sodium and potassium compounds, a feature of the invention resides in their elimination (other than as slight contaminants) from the compositions of the invention.
- compositions in accordance with the invention, are the following, and from them other suitable compositions will be apparent.
- Example lI.Sterile solution Grams Ammomia water 28.3% NH; 19.54 p-Carboxybenzenesulfonamide 50 Pyrogen-free double distilled Water, q. s.
- Example III -Dry filled capsules Kg. p-Carboxybenzenesulfonamide 4 Corn starch USP 0.8
- Yield 8000 capsules each containing 0.5 gram of pcarboxybenzenesulfonamide.
- Example I V.Sft elastic capsules p-Carboxybenzenesulfonamide "kilo-.. Peanut oil, q. s. (to form soft creamy mixture).
- Each cc. of the suspension mixture contains 1.0 gram of the p-carboxybenzenesulfonamide.
- Example V I Effervescent granule p-Carboxybenzenesulfonamide kg 4 Dulcin kg 0.025
- Each 4 gm. of granular material contains 2 gm. of pcarboxybenzenesulfonamide.
- Example VII Granale p-Carboxybenzenesulfonamide kg 4 Powdered sugar USP kg 1.5 Corn starch USP kg 0.5
- Distilled water a suflicient quantity, about 1000 cc.
- Example VIII Efiervescent tablet p-Carboxybenzenesulfonamide kg. 4 Dulcin kg 0.025 Calcium Carbonate USP powder kg 3.325
- Theoretical yield 2000 tablets, each weighing 4 grams and each containing 2 grams of p-carboxybenzenesulfonamide.
- Example X Powder p-Carboxybenzenesulfonamide 4 Powdered sugar USP 2 Yield: 2000 doses, each weighing 3 grams and each containing 2 grams of p-carboxybenzeuesulfonamide.
- composition of the invention having the p-carboxybenzenesulfonamide present in smaller or greater concentration
- the active agent could be present in as low as 1 or 2% by weight of the composition, especially if a clear aqueous solution of relatively insoluble derivatives (hereinafter mentioned) of the p-carb0xybenzenesulfonamide are to be used.
- the higher relative proportions, as 10% and more, are to be recommended and this may be even if the patient can tolerate the undiluted p-carboxybenzenesulfonamide.
- the active material in this latter case can be packaged as the pure compound and be labeled for medicinal use with instructions by the physician as to the quantity and frequency of consumption by the patient.
- a daily amount of from 2 to 16 grams may be prescribed. In most instances the daily intake will be from 4 to 8 grams.
- the attending physician can determine the proper daily consumption by physical observation of the patient and by measurement of the patients sodium and potassium balance. Based on this information, the daily administration should be regulated to approximately the minimum to bring about and maintain the desired sodium and potassium elimination.
- the ammonium salt may be utilized.
- the sodium or potassium salt may be used, but as has been mentioned, this is counterindicated as it introduces the ions which are intended to be eliminated from the body.
- Other salts may be utilized by replacing the hydrogen of the carboxyl group.
- the invention contemplates as well other derivatives of the acid, and this includes the lower alkyl esters, the amide, and either the mono or the disubstituted lower alkyl derivatives of the amide form.
- Representative compounds which may be substituted in the above examples in amounts to yield an equivalent therapeutic effeet, are the following:
- a method of increasing the elimination of an ion selected from the group consisting of sodium and potassium ions from the body which comprises administering a composition comprising not less than 1.0% by weight of p-carboxybenzenesulfonarnide to a person suffering from an abnormal retention of these ions.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
United States Patent METHOD OF PRODUCING A DIURETIC EFFECT WITH p-CARBOXYBENZENESULFONAMIDE No Drawing. Application November 24, 1952,
Serial No. 322,356
5 Claims. (Cl. 167-55) This invention relates to diuretic compositions, and more particularly to a composition containing an agent which serves to increase the elimination of cations, principally sodium and potassium.
The invention also involves the process of increasing the elimination of cations, and more particularly the sodium cation, from the body of man or other animals. This process involves the administration of the active agent and the regulation of the quantity consumed so as to bring about this desired result.
Many persons suffer from an abnormal retention of sodium, principally as the chloride. This may result in the development of edema, may precipitate an episode of congestive heart failure, or may aggravate a pre-existing hypertension. One way to overcome this is to decrease the amount of sodium chloride intake, but-this is an unsatisfactory solution for the reason that many such foods are unpalatable. That is, people object so much to the bland taste of the food that they refuse to adhere to a regime of an extremely low salt consumption.
In accordance with the present invention a composition is provided which, when consumed, makes it possible for a person to apply the desired amounts of salt to his food. The composition of the invention serves to provide for excretion of a major amount of this salt intake with the result that the patient is allowed a diet to which he will adhere and at the same time the daily salt balance approximates that resulting from moderate to severe salt restriction without the aid of this invention.
Furthermore, there are a number of clinical indications for the use of the composition of the invention. In various edematous states it is desirable to eliminate cations, and principally the sodium cations, from the body, in order to bring about a reduction of the edematous condition. By giving such a patient the composition of the invention, this condition will be markedly improved.
The value of salt restriction as a means of limiting the development of edema is well documented. The composition of the invention may be particularly useful in the patient prone to congestive heart failure.
The active agent of the composition of the invention is para-carboxybenzenesulfonamide (or 'para-sulfamylbenzoic acid), having the structural formula:
no 0 o-Q-s ORNH! This active agent may be combined with either a solid or a liquid carrier or diluent. The resulting compound may be put up in the form of tablets, powder, or capsules, or in any form which can be used for oral consumption. Likewise, the liquid preparation may be bottled or even put up in encapsulated form for ease of oral administration. The liquid form may as well be for parenteral administration and in this event precautions should of course be taken to produce a sterile composition. I
In making the composition, conventional pharmaceutical practices may be carried out andthis applies to com- 2,789,938 Patented Apr. 23, 1957 positions for either oral or parenteral use. Ordinary care should be exercised to make sure that no incompatible condition exists with respect to the diluent which is being employed. In the liquid preparation, the active ingredient may be either in complete solution or may be in suspension.
Irrespective of the particular kind of dosage form which is made, the unit dosage of the composition should contain therapeutic amounts of the active agent. Thus, a unit dosage of the ingredient will contain from 10 mg. to 16 gm., a more preferred range being from 100 mg. to 4.0 gm. The total daily oral intake for an adult should be from 0.5 to 16 grams, and most generally from 2 to 8 grams. About one-fourth these amounts would be taken parenterally. Bearing in mind that a person required to take this composition will ordinarily prefer at one time to take one or a few tablets or capsules, or one or a few tablespoons of a liquid preparation, or a few cc. of an injectable preparation, the frequency of administration is apparent.
As a further feature of the invention, compositions are provided which are free of any material amounts of sodium or potassium. As a primary purpose of the invention is to increase the elimination of these cations, it follows that it would be desirable not to introduce any sodium or potassium into the person with the active agent of the invention. As ordinary pharmaceutical compositions contain sodium and potassium compounds, a feature of the invention resides in their elimination (other than as slight contaminants) from the compositions of the invention.
Representative compositions, in accordance with the invention, are the following, and from them other suitable compositions will be apparent.
Example I.Compressea' tablets p-Carboxybenzenesulfonamide 57 lb. 13 oz. Dextrine white NF V 4 lb. 8 oz. Corn starch paste, 1 part Gelatin solution, 2 parts "i 1 8 Distilled water, q. s.
Starch USP dried-MP 3000 7 lb. 8 oz. Talc USP 3 1b. 8 oz. Magnesium stearate purif. imp. powd 3 oz.
Total weight granulation lb.
Compress into 0.65 gram tablets each containing 0.5 gram of p-carboxybenzenesulfonamide. Theoretical yield: 52,500.
Example lI.Sterile solution Grams Ammomia water 28.3% NH; 19.54 p-Carboxybenzenesulfonamide 50 Pyrogen-free double distilled Water, q. s.
Example III.-Dry filled capsules Kg. p-Carboxybenzenesulfonamide 4 Corn starch USP 0.8
" Yield: 8000 capsules each containing 0.5 gram of pcarboxybenzenesulfonamide.
Example I V.Sft elastic capsules p-Carboxybenzenesulfonamide "kilo-.. Peanut oil, q. s. (to form soft creamy mixture).
Make into soft elastic capsules of a suitable size, each capsule representing 500 mg. p-carboxybenzenesulfonamide.
Example V.-Saspension (oral) Distilled Water, q. s. ad.
Each cc. of the suspension mixture contains 1.0 gram of the p-carboxybenzenesulfonamide.
Example V I .Effervescent granule p-Carboxybenzenesulfonamide kg 4 Dulcin kg 0.025
Calcium carbonate powder USP kg 3.375
Corn starch paste 12.5% 1000 cc. allow kg 0.100
Distilled water, a sufficient quantity about 250 cc.
Citric acid fine USP granules kg 0.5 8.0
Yield: 2000 doses. Each 4 gm. of granular material contains 2 gm. of pcarboxybenzenesulfonamide.
Example VII .Granale p-Carboxybenzenesulfonamide kg 4 Powdered sugar USP kg 1.5 Corn starch USP kg 0.5
Distilled water, a suflicient quantity, about 1000 cc.
6 Yield: 2000 doses. Each 3 gm. dose of granular material contains 2 gm. of p-carboxybenzenesulfonamide.
Example VIII .Efiervescent tablet p-Carboxybenzenesulfonamide kg. 4 Dulcin kg 0.025 Calcium Carbonate USP powder kg 3.325
Corn starch paste 12.5% 1.5 liters allow kg 0.150
Distilled water, a suflicient quantity, about 0.5 liter.
Citric acid USP fine granules kg 0.47
Magnesium stearate .kg 0.03
Theoretical yield: 2000 tablets, each weighing 4 grams and each containing 2 grams of p-carboxybenzenesulfonamide.
Example IX.Efiervescent powder Kg. p-Carboxybenzenesulfonamide 4 Dulcin 0.025 Calcium carbonate USP powder 3.475 Citric acid USP powder 0.5 8.0
Yield: 2000 doses of 4 grams each, each containing 2 grams of p-carboxybenzenesulfonamide.
Example X .Powder p-Carboxybenzenesulfonamide 4 Powdered sugar USP 2 Yield: 2000 doses, each weighing 3 grams and each containing 2 grams of p-carboxybenzeuesulfonamide.
Other examples of the composition of the invention having the p-carboxybenzenesulfonamide present in smaller or greater concentration will be apparent. Thus the active agent could be present in as low as 1 or 2% by weight of the composition, especially if a clear aqueous solution of relatively insoluble derivatives (hereinafter mentioned) of the p-carb0xybenzenesulfonamide are to be used. However, because of the relatively large amount of the active agent which must be taken daily, the higher relative proportions, as 10% and more, are to be recommended and this may be even if the patient can tolerate the undiluted p-carboxybenzenesulfonamide. The active material in this latter case can be packaged as the pure compound and be labeled for medicinal use with instructions by the physician as to the quantity and frequency of consumption by the patient.
As has been mentioned, a daily amount of from 2 to 16 grams may be prescribed. In most instances the daily intake will be from 4 to 8 grams. The attending physician can determine the proper daily consumption by physical observation of the patient and by measurement of the patients sodium and potassium balance. Based on this information, the daily administration should be regulated to approximately the minimum to bring about and maintain the desired sodium and potassium elimination.
Although the invention has been described with particular reference to p-carboxybenzenesulfonamide, numerous derivatives of it may be employed as they presumably yield this acid in the body. For example, as is evident from Example II, the ammonium salt may be utilized. The sodium or potassium salt may be used, but as has been mentioned, this is counterindicated as it introduces the ions which are intended to be eliminated from the body. Other salts may be utilized by replacing the hydrogen of the carboxyl group.
The invention contemplates as well other derivatives of the acid, and this includes the lower alkyl esters, the amide, and either the mono or the disubstituted lower alkyl derivatives of the amide form. Representative compounds which may be substituted in the above examples in amounts to yield an equivalent therapeutic effeet, are the following:
Ethyl p-sulfamylbenzoate p-Sulfamy1benzamide CHaNHOC SOzNHz p-Sulfamyl-N-methylbenzamlde (CHa)2NOC SOgNHs p-Sulfamyl-N,N dlmethylbenzamide 3 1) 2 O C S OzNHz p-Sulfamyl-N,N-di-n-propylbenzamide Ill-04119020 SOzNHQ n-Butyl p-sultamylbenzoate OHOzC Cs sec-Butyl p-sulfamylbenzoate S OgNHt .7 a ll Cyclohexyl p-sulfamylbenzoate tert.-Buty1 p-sulfamylbenzoate 2-diethylaminoethyl p-sulfamylbenzoate hydrochloride 2-diethy1aminoethyl p-sulfamylbenzamide hydrochloride NHzNHO C SOzN H2 p-Sulfamylbenzoyl hydrazine SO.NH.
m-Carboxybenzenesulfonamide S OzNH:
o-Carboxybenzenesulfonamide NHzNH O C I @s 021N112 m-Sulfamylbenzoyl hydrazine S OzN H2 O-Sulfumylbenzoyl hydrazine o-Chloro- -sulfamylbenzoie acid CHsO p-Sulfamyl-o-methoxybenzoic acid sium ions from the body which consists in administering to a living person suffering from an abnormal retention of these ions p-carboxybenzenesulfonamide in an amount suflicient to eliminate the excess sodium and potassium ions and bring about the desired electrolyte balance in the person.
2. The process of increasing the elimination of an ion selected from the group consisting of sodium and potassium ions from the body which consists in orally administering to a living person suffering from an abnormal retention of these ions p-carboxybenzenesulfonamide in an amount sufiicient to eliminate the excess sodium and potassium ions and bring about the desired electrolytic balance in the person.
3. The process of increasing the elimination of an ion selected from the group consisting of sodium and potassium ions from the body which consists in parenterally administering to a living person suifering from an abnormal retention of these ions p-carboxybenzenesulfonamide in an amount sufficient to eliminate the excess sodium and potassium ions and bring about the desired electrolyte balance in the person.
4. The process of increasing the elimination of an ion selected from the group consisting of sodium and potassium ions from the body which consists in administering to a living person suffering from an abnormal retention of these ions from A; to 16 grams daily of p-carboxybenzenesulfonamide in an amount suflicient to eliminate the excess sodium and potassium ions and bring about the desired electrolyte balance in the person.
5. A method of increasing the elimination of an ion selected from the group consisting of sodium and potassium ions from the body Which comprises administering a composition comprising not less than 1.0% by weight of p-carboxybenzenesulfonarnide to a person suffering from an abnormal retention of these ions.
References Cited in the file of this patent UNITED STATES PATENTS Miller Aug. 26, 1952 Fiechtinger Dec. 29, 1953 OTHER REFERENCES
Claims (1)
1. THE PROCESS OF INCREASING THE ELIMINATION OF AN ION SELECTED FROM THE GROUP CONSISTING OF SODIUM AND POTASSIUM IONS FROM THE BODY WHICH CONSISTS IN ADMINISTERING TO A LIVING PERSON SUFFERING FROM AN ABNORMAL RETENTION OF THESE IONS P-CARBOXYBENZENESULFONAMIDE IN AN AMOUNT SUFFICIENT TO ELIMINATE THE EXCESS SODIUM AND POTASSIUM IONS AND BRING ABOUT THE DESIRED ELECTROLYTE BALANCE IN THE PERSON.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US322356A US2789938A (en) | 1952-11-24 | 1952-11-24 | Method of producing a diuretic effect with p-carboxybenzenesulfonamide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US322356A US2789938A (en) | 1952-11-24 | 1952-11-24 | Method of producing a diuretic effect with p-carboxybenzenesulfonamide |
Publications (1)
Publication Number | Publication Date |
---|---|
US2789938A true US2789938A (en) | 1957-04-23 |
Family
ID=23254519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US322356A Expired - Lifetime US2789938A (en) | 1952-11-24 | 1952-11-24 | Method of producing a diuretic effect with p-carboxybenzenesulfonamide |
Country Status (1)
Country | Link |
---|---|
US (1) | US2789938A (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2967130A (en) * | 1957-09-05 | 1961-01-03 | Robert G Sanders | p-sulfamyl beta-hydroxyethyl carbanilate diuretic compositions |
US2991283A (en) * | 1957-01-28 | 1961-07-04 | Bofors Ab | Substituted amino alkyl esters of paraalkyl sulfamide benzoic acids |
DE1146873B (en) * | 1960-02-16 | 1963-04-11 | British Drug House Ltd | Process for the preparation of 4-chloro-3-sulfamylbenzoic acid and its alkali metal salts |
DE1153745B (en) * | 1960-05-09 | 1963-09-05 | Parke Davis & Co | Process for the preparation of 4-halo-3-sulfamoylbenzoic acid esters |
US3110815A (en) * | 1959-09-12 | 1963-11-12 | Quarzlampen Gmbh | Remote control apparatus for moving an operating lamp |
US3112337A (en) * | 1960-05-09 | 1963-11-26 | Parke Davis & Co | 4-halo-3-sulfamoylbenzoic acid esters |
US3162651A (en) * | 1961-05-08 | 1964-12-22 | Fidelity Union Trust Company | Thienylalkyl esters of 3-sulphamyl-4-chlorobenzoic acid |
US3165512A (en) * | 1960-09-23 | 1965-01-12 | Geigy Chem Corp | Morpholinones |
US3346568A (en) * | 1961-09-14 | 1967-10-10 | Ciba Geigy Corp | 2-amino-5-sulfamyl-benzoic acid hydrazides |
US20080131506A1 (en) * | 2005-02-16 | 2008-06-05 | Solvay (Societe Anonyme) | Tablets Comprising a Biologically Active Substance and an Excipient Containing Calcium Carbonate |
WO2008130332A1 (en) | 2007-04-20 | 2008-10-30 | Unimed Pharma, Spol. S R.O. | Subsituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2608507A (en) * | 1949-08-20 | 1952-08-26 | Sharp & Dohme Inc | Dialkyl sulfamyl benzoic acids |
US2664439A (en) * | 1951-07-25 | 1953-12-29 | Ruhrchemie Ag | Process for the production of benzoic-p-sulfonamide |
-
1952
- 1952-11-24 US US322356A patent/US2789938A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2608507A (en) * | 1949-08-20 | 1952-08-26 | Sharp & Dohme Inc | Dialkyl sulfamyl benzoic acids |
US2664439A (en) * | 1951-07-25 | 1953-12-29 | Ruhrchemie Ag | Process for the production of benzoic-p-sulfonamide |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2991283A (en) * | 1957-01-28 | 1961-07-04 | Bofors Ab | Substituted amino alkyl esters of paraalkyl sulfamide benzoic acids |
US2967130A (en) * | 1957-09-05 | 1961-01-03 | Robert G Sanders | p-sulfamyl beta-hydroxyethyl carbanilate diuretic compositions |
US3110815A (en) * | 1959-09-12 | 1963-11-12 | Quarzlampen Gmbh | Remote control apparatus for moving an operating lamp |
DE1146873B (en) * | 1960-02-16 | 1963-04-11 | British Drug House Ltd | Process for the preparation of 4-chloro-3-sulfamylbenzoic acid and its alkali metal salts |
DE1153745B (en) * | 1960-05-09 | 1963-09-05 | Parke Davis & Co | Process for the preparation of 4-halo-3-sulfamoylbenzoic acid esters |
US3112337A (en) * | 1960-05-09 | 1963-11-26 | Parke Davis & Co | 4-halo-3-sulfamoylbenzoic acid esters |
US3165512A (en) * | 1960-09-23 | 1965-01-12 | Geigy Chem Corp | Morpholinones |
US3162651A (en) * | 1961-05-08 | 1964-12-22 | Fidelity Union Trust Company | Thienylalkyl esters of 3-sulphamyl-4-chlorobenzoic acid |
US3346568A (en) * | 1961-09-14 | 1967-10-10 | Ciba Geigy Corp | 2-amino-5-sulfamyl-benzoic acid hydrazides |
US20080131506A1 (en) * | 2005-02-16 | 2008-06-05 | Solvay (Societe Anonyme) | Tablets Comprising a Biologically Active Substance and an Excipient Containing Calcium Carbonate |
US7892576B2 (en) * | 2005-02-16 | 2011-02-22 | Solvay (Societe Anonyme) | Tablets comprising a biologically active substance and an excipient containing calcium carbonate |
WO2008130332A1 (en) | 2007-04-20 | 2008-10-30 | Unimed Pharma, Spol. S R.O. | Subsituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use |
AU2008241590B2 (en) * | 2007-04-20 | 2012-06-21 | Unimed Pharma, Spol. S R.O. | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use |
RU2474574C2 (en) * | 2007-04-20 | 2013-02-10 | ЮНИМЕД ФАРМА, спол. с.р.о. | Substituted sulphonamides, method for production thereof, medicinal agents containing said sulphonamides and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Freis et al. | Treatment of essential hypertension with chlorothiazide (Diuril): its use alone and combined with other antihypertensive agents | |
CA2272711C (en) | Method for treating renal failure | |
US2789938A (en) | Method of producing a diuretic effect with p-carboxybenzenesulfonamide | |
Dent et al. | Studies in osteopetrosis | |
US4315028A (en) | Method of treatment of rheumatoid arthritis | |
JPH06502148A (en) | antidepressants | |
US3781429A (en) | Method of inhibiting ulcerogenesis induced by non-steroidal anti-inflammatory agents | |
EP0154009B1 (en) | Use of a thiazide diuretic for the manufacture of a non-diuretic antihypertensive medicament | |
US2798837A (en) | Achlorhydria composition | |
Fitzsimons et al. | Pruritus of polycythaemia vera: a place for pizotifen? | |
US20020082299A1 (en) | Method for reducing body weight | |
US3867539A (en) | Method of producing anorexia as a treatment for obesity | |
EP0070714A1 (en) | Use of ibuprofen or flurbiprofen for the manufacture of a medicament for treating respiratory disorders | |
US2987442A (en) | Method of treating hypertension with [2-(2, 6-dimethylphenoxy)-propyl]-trimethyl ammonium salts | |
US3917832A (en) | Compositions comprising d-thyroxine and d-triiodothyronine | |
US3144387A (en) | Anti-inflammatory compositions | |
US4439451A (en) | Treatment of the blood-brain barrier with flurbiprofen | |
AU4515489A (en) | Treatment of hypertension | |
US5932252A (en) | Method and composition for treatment of osteoporosis | |
US4447451A (en) | Treatment of adult respiratory distress syndrome | |
US4895851A (en) | Use of oxoquinazoline derivatives in the treatment of hyperuricaemia | |
US3644643A (en) | Method of reducing intraocular pressure using glycine | |
US3362879A (en) | Tyrosine tranquilizing compositions and methods of treatment | |
Hilton | Effects of mercurial diuresis in patients with ascites due to cirrhosis | |
US2967130A (en) | p-sulfamyl beta-hydroxyethyl carbanilate diuretic compositions |